The Hematology/Oncology Pharmacy Association has helped establish practical guidance for Investigational Services metrics and site utilization.

The metrics subgroup of the HOPA Investigational drug services (IDS) special interest group recently conducted a survey-based project to help establish practical guidance for IDS metrics and site utlity. Three surveys were sent to HOPA IDS professionals to document how metrics were currently gathered at various sites, categorize and define additional approaches, and create a list of recommended metrics for every IDS site to track. The recommended metrics can serve as a basis for standardization and benchmarking for sites mired in the complexity of research protocols.

The results have been published in the American Journal of Health-Systems Pharmacy.


Authors: Molly Schmidt, PharmD, BCPS, BCOP, CSP; Lisa Janssen Carlson, PharmD, BCOP; Jennifer Murphy, PharmD, BCOP, Sapna R Amin, PharmD, BCOP; Robin Lockhorst, PharmD, BCOP, BCPS; and Kyle Luedtke, PharmD

Read the abstract

An image of chronic lymphocytic leukemia cells under a microscope
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Cristina V. Martinez, PharmD, PGY2 Oncology Pharmacy Resident, and Hunter Sowell, PharmD, BCOP, Clinical Pharmacy Specialist Oncology, analyze the potential role for pirtobrutinib in treating chronic lymphocytic leukemia and small lymphocytic lymphoma.

A graphic of a man's lungs on a blue background
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Taletrectinib

Benjamin Pastore, PharmD, PGY2 Adult Oncology Pharmacy Resident, and Jasmine Patel, PharmD, BCOP, Clinical Pharmacy Specialist - Thoracic Oncology, discuss the potential role of taletrectinib in the treatment of metastatic non-small cell lung cancer.

An image of a doctor looking at an x-ray of lungs with cancer
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Zongertinib

Reyam Katchi, PharmD, PGY2 Hematology/Oncology Pharmacy Resident, and Kiera Roubal, PharmD, Oncology Clinical Pharmacist, break down the potential role for zongertinib in the treatment of non-squamous NSCLC with HER2 TKD activating mutations.